Diep, Jonathan
Ooi, Yaw Shin https://orcid.org/0000-0001-9014-1365
Wilkinson, Alex W.
Peters, Christine E.
Foy, Eileen
Johnson, Jeffrey R.
Zengel, James
Ding, Siyuan
Weng, Kuo-Feng
Laufman, Orly
Jang, Gwendolyn
Xu, Jiewei
Young, Tracy
Verschueren, Erik
Kobluk, Kristi J.
Elias, Joshua E.
Sarnow, Peter
Greenberg, Harry B.
Hüttenhain, Ruth
Nagamine, Claude M.
Andino, Raul https://orcid.org/0000-0001-5503-9349
Krogan, Nevan J. https://orcid.org/0000-0003-4902-337X
Gozani, Or https://orcid.org/0000-0002-1365-4463
Carette, Jan E. https://orcid.org/0000-0002-5187-8070
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (DP2 AI104557, AI104557, AI104557, AI091575, AI091575, AI135031, AI140186, AI091575, AI091575, AI091575, AI091575, AI104557, AI021362, AI104557, AI091575, AI091575, AI140186, AI091575, AI091575)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM079641, GM079641)
Article History
Received: 11 March 2019
Accepted: 26 July 2019
First Online: 16 September 2019
Competing interests
: O.G. is a co-founder of EpiCypher and Athelas Therapeutics.